| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2849622 | American Heart Journal | 2010 | 9 Pages |
Abstract
ENGAGE AF-TIMI 48 is a phase 3 comparison of the novel oral factor Xa inhibitor edoxaban to warfarin for the prevention of thromboembolism in patients with atrial fibrillation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Christian T. MD, Robert P. MD, SM, Elliott M. MD, Sharon E. MS, Tomas MD, Michele MD, PhD, James PharmD, Indravadan MD, Minggao PhD, Dan PhD, Carolyn H. BS, Eugene MD,